Wyeth Sales Growth Not Dependent On Effexor XR, CEO Essner Says

The company plans to file six NDAs over the next 24 months, including the Effexor follow-on drug DVS-233. Wyeth believes the antidepressant market will eventually "start to swing back" since the products are safe and effective "within the confines of their labeling."